Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)
Clin. transl. oncol. (Print)
; 14(8): 564-574, ago. 2012.
Article
de En
| IBECS
| ID: ibc-126952
Bibliothèque responsable:
ES1.1
Localisation: BNCS
ABSTRACT
Angiogenesis is a cornerstone in the process of hepatocarcinogenesis. In the sorafenib era, other antiangiogenic targeted drugs, such as monoclonal antibodies and a new generation of tyrosine kinase inhibitors, have been shown in phase II trials to be safe and effective in the treatment of advanced hepatocellular carcinoma. Several currently active phase III trials are testing these drugs, both in first- and second-line settings. Strategies to overcome primary and acquired resistance to antiangiogenic therapy are urgently needed. Novel biomarkers may help in improving the efficacy of drugs targeting angiogenesis (AU)
Recherche sur Google
Collection:
06-national
/
ES
Base de données:
IBECS
Sujet principal:
Carcinome hépatocellulaire
/
Inhibiteurs de l'angiogenèse
/
Tumeurs du foie
Type d'étude:
Guideline
Limites:
Humans
Langue:
En
Journal:
Clin. transl. oncol. (Print)
Année:
2012
Type de document:
Article